Back to results
US 2009/0253138 A1Published application
Kif20a directed diagnostics for neoplastic disease
OwnerElias GEORGES, Anne-Marie BONNEAUinventors
Life of this patent
Estimating the term…
Abstract
Disclosed are methods for diagnosing cancer in a test cell sample or fluid sample by detecting an increase in the level of expression of KIF20A in the test cell sample or fluid sample as compared to the level of expression of KIF20A in a control cell sample or fluid sample isolated from a normal subject.
Claims34
A method for detecting a neoplasm comprising:
- a) obtaining a potentially neoplastic test sample and a corresponding non-neoplastic control sample;
- b) detecting a level of KIF20A expression in the test sample and in the control sample;
- and
- c) comparing the level of KIF20A expression in the test sample to the level of KIF20A expression in the control sample,
- the test sample being neoplastic if the level of KIF20A expression in the test sample is detectably greater than the level of KIF20A expression in the control sample.
2 more elements
A method for detecting a neoplasm comprising:
- a) obtaining a potentially neoplastic test sample and a non-neoplastic control sample;
- b) detecting a level of KIF20A expression in the test sample and in the control sample;
- c) detecting a level of expression of at least one of TRIM59, TTK, SLC7A5, and/or UHRF1;
- and
- d) comparing the level of KIF20A expression and the level of expression of at least one of TTK, SLC7A5, TRIM59 and/or UHRF1 in the test sample to the level of KIF20A expression and the level of expression of the at least one of TTK, SLC7A5, TRIM59 and/or UHRF1 in the control sample,
- the test sample being neoplastic if the levels of expression of KIF20A and the at least one of TTK, SLC7A5, TRIM59 and/or UHRF1 in the test sample are detectably greater than the levels of expression of KIF20A and the at least one of TTK, SLC7A5, TRIM59 and/or UHRF1 in the control sample.
3 more elements
A kit for diagnosing or detecting neoplasia, comprising:
- a) a first probe specific for the detection of KIF20A;
- and
- b) a second probe specific for the detection of a neoplasia marker selected from the group consisting of TTK, SLC7A5, TRIM59, UHRF1, and combinations thereof,
Dependencies are inferred from the claim text.